MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Retronasal olfactory function in Parkinson’s disease

E. Aubry-Lafontaine, C. Tremblay, P. Durand-Martel, N. Dupré, J. Frasnelli (Trois-Rivières, QC, Canada)

Meeting: 2019 International Congress

Abstract Number: 1526

Keywords: Olfactory dysfunction

Session Information

Date: Wednesday, September 25, 2019

Session Title: Non-Motor Symptoms

Session Time: 1:15pm-2:45pm

Location: Agora 3 West, Level 3

Objective: The objective of this study was to compare orthonasal and retronasal olfactory function in PD patients and compare them to NPOD participants and to healthy controls. We hypothesized that the combined testing of orthonasal and retronasal olfactory functions allows to distinguish PD patients from patients with NPOD and healthy controls in regards to their different olfactory impairment patterns.

Background: Olfactory dysfunction (OD) is one of the first clinical signs observed in Parkinson’s disease (PD) and appears several years before the presence of motor disturbance. As a highly reliable symptom OD is present in up to 90% of PD patients. Thus, olfactory testing has the potential to serve as tool for early detection of PD. However, OD is not specific to PD as it affects 20% of the general population. The sense of smell includes an orthonasal and a retronasal component; in some forms of OD, retronasal olfactory function is preserved. We aimed to evaluate whether combined testing of orthonasal and retronasal olfaction allows for discriminating between PD-related OD and non-parkinsonian OD (NPOD).

Method: A total of 32 PD patients, 25 NOPD patients and 15 healthy controls underwent orthonasal (Sniffin’Sticks test) and retronasal (aromatized powders) olfactory testing.

Results: Both orthonasal and retronasal olfaction are impaired in PD and NPOD patients, compared to controls; NPOD patients had significantly better orthonasal scores than PD patients. As a consequence, the ratio of the retronasal score/ orthonasal score was significantly higher in PD than in both other groups. In Parkinson-free participants, orthonasal and retronasal scores were significantly correlated; no such correlation could be observed in PD patients.

Conclusion: For tests of retronasal olfaction, PD patients seem to rely on particular mechanisms to compensate for olfactory loss. Combined orthonasal and retronasal olfactory testing may contribute to differentiate PD patients from patients with NPOD.

To cite this abstract in AMA style:

E. Aubry-Lafontaine, C. Tremblay, P. Durand-Martel, N. Dupré, J. Frasnelli. Retronasal olfactory function in Parkinson’s disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/retronasal-olfactory-function-in-parkinsons-disease/. Accessed May 8, 2025.
  • Tweet
  • Email
  • Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/retronasal-olfactory-function-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley